Bipolar disorder<unk>  is used to treat manic or mixed episodes associated with bipolar I disorder in India. It has been found that the<unk>  improves manic symptoms as well as mixed episode symptoms of patients with bipolar I disorder and has been considered an effective and well-tolerated treatment for this condition. Bipolar disorder is associated with overactive protein kinase C (PKC) intracellular signaling. To date, there have been three phases of clinical trials. And, in the phase III trials,<unk>  reduced the total Young Mania Rating Scale (YMRS) score from 33.1 to 17.8. A significant (p < 0.001) improvement in Montgomery–Åsberg Depression Rating Scale (MADRS) score was observed for<unk>  (4.8 to 2.5). The<unk>  is well-tolerated by the subjects as depicted in the changes in Clinical Global Impression-Severity of Illness scores.
Endoxifen
Tamoxifen
Anastrozole
Salvestrol
N-Desmethyltamoxifen
Norendoxifen
Bazedoxifene
N,N-Didesmethyltamoxifen